Lawrence Kenyon

Form D signer

Lawrence Kenyon

Interim Chief Executive Officer, CFO, Treas & Sec'y at Outlook Therapeutics

Form D signer

Capital raised by Outlook Therapeutics

—

2 Form D filings · first filed Jan 2025 · Iselin, NJ

CURRENT ROLE: Interim Chief Executive Officer, CFO, Treas & Sec'y
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 1 ↗

Career

1 company on file

Outlook TherapeuticsBiotech · Iselin, NJsince Jan 2025

Interim Chief Executive Officer, CFO, Treas & Sec'y

Signatory on Outlook Therapeutics's Form D filings

Company filings

via EDGAR · Form D for Outlook Therapeutics2

DateCompanyFormAmountRole on filing

Apr 23, 2026Outlook TherapeuticsForm D—Interim Chief Executive Officer, CFO, Treas & Sec'y

Form DApr 23, 2026 · Outlook Therapeutics—as Interim Chief Executive Officer, CFO, Treas & Sec'y

Jan 17, 2025Outlook TherapeuticsForm D—Interim Chief Executive Officer, CFO, Treas & Sec'y

Form DJan 17, 2025 · Outlook Therapeutics—as Interim Chief Executive Officer, CFO, Treas & Sec'y

Overview

Last filing Apr 23, 2026

Lawrence Kenyon is on file as Interim Chief Executive Officer, CFO, Treas & Sec'y at Outlook Therapeutics in Iselin, NJ. Outlook Therapeutics has 2 Form D filings on record. Lawrence Kenyon appears as a signatory on the company's filings.

Teammates

Outlook Therapeutics · 1

Julian GangolliDirector

Products

Outlook Therapeutics · 1

ONS-5010/LYTENAVA™ (bevacizumab-vikg)Retinal Disease Treatment

This product is an innovative ophthalmic formulation of bevacizumab specifically designed to meet FDA standards. It is intended for the treatment of various retinal diseases, particularly wet age-related macular degeneration.